ABSTRACT: Chronic kidney disease (CKD) results in significant dyslipidemia and profound changes in lipid and lipoprotein metabolism. The associated dyslipidemia, in turn, contributes to progression of CKD and its cardiovascular complications. To gain an in-depth insight into the disorders of lipid metabolism in advanced CKD, we applied UPLC-HDMS-based lipidomics to measure serum lipid metabolites in 180 patients with advanced CKD and 120 age-matched healthy controls. We found significant increases in the levels of total free fatty acids, glycerolipids, and glycerophospholipids in patients with CKD. The levels of free fatty acids, glycerolipids, and glycerophospholipids directly correlated with the level of serum triglyceride and inversely correlated with the levels of total cholesterol and eGFR. A total of 126 lipid species were identified from positive and negative ion modes. Out of 126, 113 identified lipid species were significantly altered in patients with CKD based on the adjusted FDR method. These results pointed to profound disturbance of fatty acid and triglyceride metabolisms in patients with CKD. Logistic regression analysis showed strong correlations between serum methyl hexadecanoic acid, LPC(24:1), 3-oxooctadecanoic acid, and PC(20:2/24:1) levels with eGFR and serum creatinine levels (R > 0.8758). In conclusion, application of UPLC-HDMSbased lipidomic technique revealed profound changes in lipid metabolites in patients with CKD. The observed increases in serum total fatty acids, glycerolipids, and glycerophospholipids levels directly correlated with increased serum triglyceride level and inversely correlated with the eGFR and triglyceride levels.
INTRODUCTION
By promoting tubulo-interstitial fibrosis and glomerulosclerosis the fibrotic process constitutes the final pathway in progression of all forms of chronic kidney disease (CKD). Renal fibrosis is characterized by myofibroblasts transformation, accumulation of fibrillary collagen, loss of capillary network, and inflammatory cell infiltration. 1 Earlier studies have demonstrated the role of lipid mediators in progression of CKD. 2−5 In fact, recent in vivo and in vitro studies demonstrated the role of impaired fatty acid oxidation, depressed mitochondrial ATP generation, and enhanced reactive oxygen species production in the pathogenesis of oxidative stress, tubular epithelial cell death, and interstitial inflammation and fibrosis. 6 Different kidney diseases result in marked alterations of lipid metabolism and serum lipid profile. 7 The associated lipid disorders, in turn, contribute to progression of kidney disease and its numerous comorbidities including cardiovascular disease, impaired energy metabolism, diminished exercise capacity, and various other complications. Severity of renal failure and presence and severity of proteinuria independently impact the nature of lipid disorders in patients with kidney disease. 8 In addition, dietary and drug regimens and renal replacement therapies (i.e., hemodialysis, peritoneal dialysis, and renal transplantation) significantly affect the lipid profile in this population. 9, 10 Although the nature and mechanisms of the abnormalities of serum lipid and lipoproteins in CKD and nephrotic syndrome are well-known, their effect on the lipid metabolites have not been fully elucidated. In the past several years, lipidomics has been increasingly used to determine the changes of lipid metabolites and identify the biomarker of various diseases in animal and humans. 11, 12 Ultra performance liquid chromatography-quadrupole time-of-flight high-definition mass spectrometry (UPLC-QTOF/HDMS) has been increasingly applied to lipidomics. 13−17 A large number of clinical studies demonstrated that abnormal lipid metabolism and serum lipid profile may contribute to the pathogenesis and progression of CKD, and a few studies have addressed the lipidomic profile of kidney diseases using untargeted lipidomic approach. 18 Lipidomic studies have demonstrated remarkable elevation of serum free fatty acid (FFA), saturated FFA, eicosanoid, lysophosphatidyl ethanolamine, and lysophosphatidyl inositol levels in prehemodialysis patients compared to the healthy controls. 19 Lipidomics has been applied to the determination of the lipid profile of low density lipoprotein (LDL), which showed significant increases in triacylglycerides and significant decreases in phosphatidylcholines, plasmenyl ethanolamines, sulfatides, ceramides, and cholesterol sulfate in patients with advanced CKD. 20 In the present study, we conducted an untargeted serum lipidomic analysis in a group of patients with advanced CKD and a group of healthy controls using UPLC-QTOF/ HDMS.
METHODS

Chemicals and Reagents
Ostro 96-well plate was provided by Waters Technologies (Shanghai) Ltd. (Shanghai, China). Formic acid and ammonium formate were purchased from Sigma Chemical Co., Ltd. (Sigma Corp., St. Louis, MO). LC-grade chloroform, methanol, 2-propanol, and acetonitrile were purchased from the Baker Chemical Co. (Phillipsburg, NJ). Lipid analytical standards were purchased from the Avanti polar lipids Inc. (Alabaster, Alabama). Ultra purity water was prepared using a Milli-Q water purification system (Billerica, MA). Other chemicals were of analytical grade, and their purity was above 99.5%.
Participants
In this cross-sectional study, patients with CKD were recruited at the Xi'an Fourth Hospital and the Traditional Chinese Medicine Hospital between February 2013 and November 2014. Serum from a total of 200 adult individuals (>18 years old), including 120 patients and 80 healthy controls, were collected for the discovery phase and from an additional 100 individuals, including 60 patients and 40 healthy controls for the validation phase. Patients with stage 4 and 5 were referred by nephrologists and were diagnosed based on clinical criteria (i.e., kidney damage, reduced estimated glomerular filtration rate (eGFR) for at least 3 months, and in some cases kidney biopsy). Patients with acute kidney injury, liver disease, patients treated with immunosuppressive agents in the past six months, or chemotherapy within the past two years, as well as patients undergoing chronic dialysis or kidney transplantation were excluded. The underlying causes of CKD were hypertension (n = 100), chronic tubulointerstitial nephritis (n = 22), chronic glomerulonephritis (n = 42), and obstructive uropathy (n = 16). To isolate the effects of CKD from those caused by systemic disorders, patients with diabetes, lupus erythematosus, amyloidosis etc. were excluded from the study. The study was approved by the Ethical Committee, and all patients had been given written informed consent prior to entering the study.
Demographics and Medical Information
Baseline information included sex, age, body mass index (BMI), blood pressure, primary renal diseases, and medication histories. Blood samples were obtained after an overnight fasting. Serum was immediately separated by centrifugation and stored at −80°C. The eGFR was calculated using the modified equation of Diet of Renal Disease. Serum biochemistry was determined by Olympus AU640 automatic analyzer. Serum high sensitivity C-reactive protein (CRP) was measured by an automated immunoturbidimetric assay. Serum interleukin-6 and tumor necrosis factor-α (TNF-α) were measured using the commercially available ELISA kits.
Lipid Profiling
UPLC-HDMS was used for the determination of lipid profile of all samples. The lipid profile procedure including sample preparation, lipid separation, lipid detection, data preprocessing, and statistical analysis for lipid identification was performed following our published protocols with minor modifications. 21 Briefly, serum total lipids were extracted using Ostro 96-well plate. One hundred microliters of serum sample was loaded into each well in Ostro preparation plate fitted onto a vacuum manifold. Three hundred microliters of elution solvent (1:1, CHCl 3 /CH 3 OH) was added to each well and mixed aspirating the mixture 10× by a micropipette. A vacuum of approximately 15″ Hg was used to the plate until the solvent was drained. This step was repeated 3 times and obtained the total extract to approximately 900 μL. The eluate fraction was dried down under nitrogen and reconstituted with 200 μL 1:1 (v/v) CHCl 3 /CH 3 OH. The extracted sample was then injected into the UPLC-HDMS system. Chromatographic separation was carried out at 45°C on an ACQUITY UPLC HSS T3 column (2.1 × 100 mm, 1.8 μm, UK). A gradient of 10 mM ammonium formate in 2-propanol/acetonitrile (90/10) in 0.1% formic acid and 10 mM ammonium formate in ACN/H 2 O (60/40) in 0.1% formic acid was used as follows: a linear gradient from 0 to 10 min, 35.0−99.0% A, and from 10.0 to 12.0 min, 99.0− 35.0% A. The flow rate was 0.5 mL/min. The temperatures of the autosampler and column were maintained at 4 and 55°C, respectively. Every 5 μL sample solution was injected for each run. Mass spectrometry was carried out by a Xevo G2 QTof. The scan range was from 100 to 1500 m/z in both positive and negative ion modes, the cone and capillary voltages were set at 60 V and 3.0 kV, respectively. The desolvation gas and cone gas was set to 900 L/h and 50 L/h, respectively. The gas temperature and source temperature was set to 500 and 120°C, respectively. Waters Unifi software was used for the data acquisition and analysis. The raw data from UPLC-HDMS were first preprocessed by Progenesis QI (Waters, Manchester, U.K.). Principal component analysis (PCA) and orthogonal partial least-squares-discriminant analysis (OPLS-DA) were performed to discriminate between patients with CKD and healthy controls. The variables were selected based on variable importance in the projection (VIP > 1.0) from the peak intensity. We reduced the resulting matrix by removing any ion peaks with zero value in the samples to obtain consistent differential variables. Variables were selected by one-way analysis of variance (ANOVA) with a threshold of P < 0.05 in SPSS 19.0. On the basis of previous literature, the variables were identified and confirmed by comparing MS data, MS/MS fragments, molecular weights, and elemental compositions with the available reference chemicals. 22, 23 Identified lipids were subjected to further statistical analysis by univariate and multivariate statistical methods. Fold change (FC) was calculated based on mean ratios for CKD/controls. Lipids were also selected by Mann−Whitney U test with a threshold of P < 0.05. The resultant P values from ANOVA were further adjusted by a false discovery rate (FDR) based on the Hochberg-Benjamini method. Significantly altered variables were defined and further identified by a VIP > 1.0, P < 0.05, and FDR < 0.05. Variables or lipids are visualized using heatmap and z-score plots analyses. The z-score of lipids was calculated according to reference distribution of the control samples. Then each lipid was centered by the control mean and scale by the control standard deviation. Pearson correlation coefficient was performed to find the correlations between the potential lipids.
2.6. Binary Logistic Regression (BLR) and Receiver Operating Characteristics (ROC) Curve Analysis BLR and ROC curve were performed by SPSS software. On the basis of the binary outcome of patients with CKD and healthy controls as dependent variables, we developed a BLR model to find the best combination of significantly altered lipid species. The methods of the forward stepwise regression and Wald test were used for selecting altered lipid classes and assessing significance in BLR prediction model, respectively. The method was used to discover the most important lipid species until there were no more significant predictors from the data. The Wald test provided a P value to each individual lipid species to assess their significance. PLS-DA-based ROC analysis was performed for evaluating significantly altered lipid species using MedCalc 14.0.
RESULTS
General Data
To isolate the effects of CKD from those caused by systemic disorders, patients with diabetes, systemic lupus erythematosus, amyloidosis, etc. were excluded from the study. The general clinical and demographic data are presented in Table 1 . There were no significant differences in age and BMI between the two groups. Patients with CKD had higher SBP and DBP and lower eGFR compared to the healthy controls. Serum creatinine, BUN, LDL-C, and triglycerides were significantly increased, and serum HDL-C was significantly decreased in patients with CKD compared to the healthy controls. Patients with CKD had higher serum CRP, IL-6, and TNF-α levels.
Selection and Identification of Significantly Altered Lipid Classes
To evaluate the changes of lipidome in patients with CKD and find significantly altered lipid species, a two-predictive component OPLS-DA was performed using data from patients with CKD and healthy controls. The OPLS-DA score plots could readily be divided into two clusters, indicating that serum lipid metabolic patterns were significantly altered in patients with CKD ( Figure S1 ). Initially, 287 and 196 variables were selected according to the VIP values from S-plots, respectively ( Figure S1 ). On the basis of authentic standards, analogue structure of authentic chemicals or databases, 77 and 49 lipid species were identified from positive ion mode and negative ion mode, respectively. PCA score plots and the heatmap showed that 126 lipid species could separate patients with CKD from healthy controls ( Figure S2 ). Having a P < 0.05 were 113 out of 126 lipid species based on one-way ANOVA and adjusted FDR. Subsequent analysis showed that 88 out of 113 lipid species had an AUC > 0.85 based on ROC analysis and 59, 19, and 10 lipids were identified by the MS and MS/MS using databases, analogue structure of authentic chemicals, and authentic chemicals, respectively (Table 2) . PCA score plots and heatmap showed that 88 lipid species could separate patients with CKD from healthy controls (Figure 1 ). For the lipid species, 64 out of 113 have sensitivity and specificity equal to or greater than 85% ( Table 2) .
The potential relationships of the lipid species were analyzed using hierarchical clustering analyses. In accordance with their Pearson correlation coefficients, 64 lipid species and the closely associated lipids were clustered (Figure 2A ). Three main lipid classes including glycerophospholipids (PC, PE, PG, LPC, and LPE), glycerolipids (MG, DG, and TG), and fatty acids were observed in four major clusters. Additionally, SAM was further used for lipid species selection. 24 SAM identified 54 altered lipid species ( Figure 2B ). To predict diagnostic performance for each sample, predicted class probabilities was performed on 71 lipid species ( Figure 2C ). All 120 serum samples from CKD were correctly grouped with 100% sensitivity. Data from all 80 control individuals were located in the control area with 100% specificity. Therefore, these lipid species were closely associated with abnormal lipid metabolism in patients with CKD.
Significantly increased total fatty acids, glycerolipids, and glycerophospholipids were observed in patients with CKD compared to the healthy controls ( Figure 3A) . To further confirm the significant changes in serum profile with severity of CKD, we analyzed the relationships among total fatty acids, glycerolipids and glycerophospholipids, triglyceride (TG), and total cholesterol (TC) with eGFR in patients with CKD. The serum level of total fatty acids, glycerolipids, and glycerophospholipids directly correlated with serum TG and inversely correlated with the eGFR and TC (Figure 3 , panels B to C). Figure 4 showed the intensities of 60 individual lipid species. Significant increases in 6 saturated fatty acids (SFA) and 14 glycerolipids as well as significant decreases in 7 polyunsaturated fatty-acids (PUFA) and 8 glycerolipids were observed in patients with CKD. Except for 1 PC and 1 LPC, 22 glycerophospholipids were significantly increased in patients with CKD.
BLR and ROC Curve Analysis
On the basis of the 64 differential lipid species, a logistic regression model was developed to assess the potential utility of significantly altered lipid species for the discrimination between patients with CKD and healthy controls. Through a forward stepwise analysis, methyl hexadecanoic acid, LPC(24:1), 3-oxooctadecanoic acid, and PC(20:2/24:1) were identified as reliable lipid species in the regression model. Significantly increased methyl hexadecanoic acid, LPC(24:1), and 3-oxooctadecanoic acid and decreased PC(20:2/24:1) were observed in patients with CKD. 
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Validation of Four Significantly Altered Lipid Species
For validation of four lipid species, these lipid species were measured in the serum of an independent cohort. The results confirmed that the four lipid species could separate patients with CKD from the healthy controls with high sensitivity, specificity, and diagnostic performances ( Figure 5, panels A, B , and C). Diagnostic performances showed all 60 CKD samples were located in the CKD area (100% sensitivity) and 38 out of the 40 control samples were correctly grouped (95% specificity) ( Figure 5D ). Significantly increased methyl hexadecanoic acid, LPC(24:1) and 3-oxooctadecanoic acid and decreased PC(20:2/24:1) were observed in 60 patients with CKD compared to the 40 healthy controls ( Figure 6A ). To further validate candidates that might be useful in detecting CKD, we analyzed the relationship between each lipid species and eGFR and serum creatinine levels. The analysis showed that methyl hexadecanoic acid, LPC(24:1), and 3-oxooctadecanoic acid were inversely correlated while PC(20:2/24:1) were positively correlated with eGFR. Methyl hexadecanoic acid, LPC(24:1), and 3-oxooctadecanoic acid were positively correlated while PC(20:2/24:1) was inversely correlated with serum creatinine level. Figure 6 demonstrates the strong correlation between each lipid species and eGFR and serum creatinine (R > 0.8758).
DISCUSSION
In this study, we found significant increases in the serum levels of total fatty acids, glycerolipids, and glycerophospholipids in patients with CKD. The serum levels of total fatty acids, glycerolipids, and glycerophospholipids were positively correlated with the TG and inversely correlated with the eGFR and TC. In addition, we found significant increases in 7 fatty acids and 14 glycerolipids as well as significant decreases in 7 fatty acids and 8 glycerolipids in patients with CKD. Except for one PC and one LPC, twenty-two glycerophospholipids were significantly increased in patients with CKD. Increased methyl hexadecanoic acid, LPC(24:1), and 3-oxooctadecanoic acid levels as well as the decreased PC(20:2/24:1) level were chosen using BLR. These findings were confirmed using an independent cohort employed in the discovery phase.
Interestingly, our study showed that SFA levels were significantly increased while PUFA levels were significantly decreased in patients with CKD compared to the healthy controls. High levels of free fatty acids (FFA) and SFA are closely associated with a higher risk of cardiovascular disease in patients with CKD. Many studies have reported that the serum levels of FFA and SFA are significantly increased in patients with kidney disease. Increased serum FFA and SFA levels have been observed in the prehemodialysis patients compared to the healthy controls. 19 In fact, an increased serum SFA level has been shown to be associated with an increased risk of sudden cardiac death in hemodialysis patients. 25 Methyl hexadecanoic acid and 3-oxooctadecanoic acid are both SFA. Metabolomics study demonstrated that methyl hexadecanoic acid was identified from bronchoalveolar lavage fluid in preterm infants complicated by respiratory distress syndrome. 26 3-Oxooctadecanoic acid was an intermediate product in fatty acid biosynthesis, and it was converted from malonic acid via the enzyme. In humans, fatty acids are mainly formed in the liver and adipose tissue and mammary glands. Recent metabolomics study showed that 3-oxohexadecanoic acid was an important metabolite in the saliva of the γ-irradiation-induced mice. 27 Our study showed that significant increased methyl hexadecanoic acid and 3-oxooctadecanoic acid levels were well-correlated with eGFR and serum creatinine in patients with CKD, which are consistent with the above-mentioned publications. Recently, Kang et al. demonstrated downregulation of key enzymes and regulators of fatty acid oxidation and increased intracellular lipid deposition in both humans and the mouse model with tubulointerstitial fibrosis.
6 Experiments using tubular epithelial cells indicated that inhibition of fatty acid oxidation causes ATP depletion, cell death, intracellular lipid deposition, and dedifferentiation to pro-fibrotic phenotype. In contrast, restoration of fatty acid metabolism by genetic or pharmacological manipulations protected mice from tubulointerstitial fibrosis.
6 Uptake of long-chain fatty acids is facilitated by the long-chain fatty acid transporter, CD36. 28 Metabolism of fatty acid requires their transport into the mitochondria by combining fatty acids to carnitine via carnitine palmitoyltransferase 1, which is the rate-limiting enzyme in fatty acid oxidation. 29 The β-oxidation of fatty acids takes place in the mitochondria, and reduced fatty acid oxidation results in mitochondrial dysfunction and oxidative phosphorylation defect. 6 Normally, fatty acid uptake, oxidation, and synthesis are tightly balanced to avoid intracellular lipid accumulation. Reduced thiobarbituric acid-reactive substance may limit oxidative stress by associating with the assembly of PUFA in membrane lipids and lipoproteins, making the double bonds less available for attack by free radicals; inhibiting the pro-oxidant enzyme, phospholipase A2; and by upregulating antioxidant enzymes. 30 Accumulated evidence indicated that fatty acid metabolism is disturbed in patients with CKD and contributes to the increased fatty acid peroxidation and development of oxidative stress. Elevated triglyceride level is associated with cardiovascular and all-cause mortality. The metabolism of glycerolipids including MG, DG, and TG are disturbed in patients with CKD. Previous studies have found significant alterations in glycerolipids synthesis and catabolism in patients with renal cell carcinoma and CKD. 18, 31 Most of the previous studies have mainly measured total TG level in patients with CKD. In the present study, we found elevated levels of 6 TG and decreased level of one TG in patients with CKD. Reis et al. found that although total LDL was unaltered, triglyceride level of LDL was significantly increased in patients with CKD. 20 Elevation of TG is commonly accompanied by significant reduction of high-density lipoprotein cholesterols in patients with CKD. 32 Serum triglycerides are significantly increased in patients and animals with CKD. Hypertriglyceridemia in CKD is primarily due to impaired TG clearance occasioned by down-regulations of lipoprotein lipase and VLDL receptor in adipose tissues and skeletal muscles and hepatic lipase and LDL receptor related protein in the liver. 33, 34 Five DG were increased and five DG were decreased in patients with CKD in our study. Teramoto et al. reported that 3-month ingestion of exogenous DG reduced the level of abdominal fat and improved serum lipid profile in free-living hemodialysis patients. Ingestion of DAG significantly decreased serum VLDL, altered serum MG, and increased highdensity lipoprotein (HDL) levels at three months. 35 Glycerophospholipids are the main components of the cell membranes and play a major role in cell signaling, membrane anchoring, and substrate transport. Serum levels of 22 glycerophospholipids including PC, PE, LPC, LPE, and PGP were significantly altered in our patients with CKD. Previous studies have demonstrated abnormal glycerophospholipids in patients and animals with CKD. 18,36−39 For example, abnormal PC metabolism was observed in patients with mild to advanced CKD. 40 In addition, Rhee et al. have reported decreased LPC including LPC(18:1) and LPC(18:2) in advanced patients with CKD and decreased LPC(14:0), PC(34:4), PC(32:2), and PC(38:3) in patients with ESRD. 41, 42 Phospholipases can catalyze the decomposition of phospholipids to release FFA. Therefore, activation of phospholipase A2 can lead to the release of FFA, reduction of PC, and elevation of the LPC levels. These are consistent with the results of the present study which revealed significant decrease in PC(20:2/24:1) coupled with significant increases in LPC(24:1) and FFA levels in our patients with CKD. In addition, LPC is produced from PC by lecithin cholesterol acyltransferase. 43 Lee et al. demonstrated that hemodialysis patients with low LPC level have a higher risk of cardiovascular disease than those with higher LPC level. 44 Decrease in PC(20:2/24:1) and increase in LPC(24:1) are consistent with previously demonstrated deficiency of lecithin cholesterol acyltransferase and activation of phospholipase A2 in patients with CKD. 45 The main limitations of the present study are limited number of patients which precluded the ability to explore the impact of gender, age, nutritional status, systemic inflammation, and use of various drugs on the observed abnormalities of lipid metabolites in our patients with CKD. 
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